Voyager Therapeutics Inc. (VT6)

Overview

Voyager Therapeutics, Inc., established in 2013 and based in Cambridge, Massachusetts, operates as a pioneering gene therapy company. It dedicates its efforts to developing advanced treatments and next-generation platform technologies targeting severe neurological diseases. Its strategic focus encompasses the collaboration and license agreements with notable entities such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships are geared towards the research, development, and commercialization of adeno-associated virus (AAV) gene therapy products, signifying Voyager's influential role in advancing gene therapy solutions.

Products and Services

• VY-AADC: This lead clinical candidate is currently undergoing an open-label Phase 1 clinical trial targeting Parkinson's disease. VY-AADC represents a forefront initiative in addressing the debilitating effects of Parkinson's through gene therapy, aiming to provide significant improvements in the treatment regimen.
• VY-SOD102: In the preclinical stage, VY-SOD102 is being developed for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease affecting nerve cells in the brain and spinal cord. This endeavor reflects Voyager's commitment to tackling challenging neurological conditions with innovative approaches.
• VY-HTT01: Focused on Huntington's disease, VY-HTT01 is another pivotal preclinical program. Huntington's disease is a genetic disorder that causes the progressive breakdown of nerve cells in the brain. Voyager's work on VY-HTT01 demonstrates its dedication to offering hope through groundbreaking gene therapy treatments.
• VY-FXN01: This preclinical candidate targets Friedreich's ataxia, a rare inherited disease that causes nervous system damage and movement problems. VY-FXN01 represents Voyager's effort to extend its gene therapy solutions to rare and challenging neurological disorders.
• Tau Program: Voyager's Tau program, directed at treating tauopathies, encompasses Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. This initiative showcases Voyager's broad approach to combat a range of tauopathies through cutting-edge gene therapy, including tackling the intricate challenges of Alzheimer's disease.
• Spinal Muscular Atrophy (SMA): Although not detailed in the primary description, any advancements or involvement by Voyager in targeting SMA through its gene therapy platforms would aim to address another severe neurodegenerative disease, highlighting the company's wide-ranging impact in the field of neurology.